Home NDC 52904-455 Sinus Relief Severe Congestion
Product NDC 52904-455
11-digit product format 529040455
Labeler code 52904
Product ID 52904-455_2e8b8f3d-80be-4a9f-abf1-4ae5bc0e5f23
Type HUMAN OTC DRUG
Nonproprietary name Acetaminophen,Guaifenesin, Phenylephrine HCl
Dosage form TABLET
Route ORAL
Labeler Select Corporation
Application part341
Marketing category OTC MONOGRAPH FINAL
Marketing start 2012-10-15
Marketing end 0000-00-00
Substance ACETAMINOPHEN; PHENYLEPHRINE HYDROCHLORIDE; GUAIFENESIN
Active strength 325 mg/1; mg/1; mg/1
NDC exclude flag No
Listing certified through 2020-12-31
Current FDA listing Historical FDA.report record
Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 30 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Package NDC Snapshot Source SHA-256 2025-12-14 17:58 UTC · source 2025-12-05 excluded product product d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 52904-455-50 d630ba8d3edf…732f749b63fb…2025-08-27 00:01 UTC · source 2025-08-26 excluded product product f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 52904-455-50 f5e01cc5f278…a2eaf40c39c3…2025-04-01 02:39 UTC · source 2025-03-31 excluded product product 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 52904-455-50 2ef7874e63bc…57b86245f4fa…2025-03-28 20:22 UTC · source 2025-03-28 excluded product product a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 52904-455-50 a1b67e2a42f9…c4cf2c586c0d…2025-03-22 03:12 UTC · source 2025-03-21 excluded product product cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 52904-455-50 cfe11265f3b6…090c488252e2…2025-03-10 12:48 UTC · source 2025-03-10 excluded product product cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 52904-455-50 cdf11ea48f46…ba0047e9e063…2025-02-02 03:52 UTC · source 2025-01-31 excluded product product 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 52904-455-50 302b2466d912…e7b80fea0513…2025-01-20 13:05 UTC · source 2025-01-20 excluded product product ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 52904-455-50 ed331223b511…672a5bd82f5f…2025-01-11 03:41 UTC · source 2025-01-10 excluded product product 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 52904-455-50 0efc9e666f02…f202fb6c5f17…2024-11-09 02:27 UTC · source 2024-11-08 excluded product product ad56d346431e…cc804d4bbf1e…2024-11-09 02:27 UTC · source 2024-11-08 excluded package package 52904-455-50 ad56d346431e…cc804d4bbf1e…2024-10-04 04:10 UTC · source 2024-10-03 excluded product product 367a005e9d99…383a685ebd0f…2024-10-04 04:10 UTC · source 2024-10-03 excluded package package 52904-455-50 367a005e9d99…383a685ebd0f…2024-07-10 04:00 UTC · source 2024-07-09 excluded product product 557ba5c1ecfa…9c80585c8c6e…2024-07-10 04:00 UTC · source 2024-07-09 excluded package package 52904-455-50 557ba5c1ecfa…9c80585c8c6e…2024-05-28 21:12 UTC · source 2024-05-28 excluded product product 8af77b9d5b6f…d9bbb34c5368…2024-05-28 21:12 UTC · source 2024-05-28 excluded package package 52904-455-50 8af77b9d5b6f…d9bbb34c5368…2024-05-15 03:39 UTC · source 2024-05-14 excluded product product 834df4deac94…adcc014656a3…2024-05-15 03:39 UTC · source 2024-05-14 excluded package package 52904-455-50 834df4deac94…adcc014656a3…2024-03-11 06:39 UTC · source 2024-03-08 excluded product product 1332a3947898…d4bfe170f9cd…2024-03-11 06:39 UTC · source 2024-03-08 excluded package package 52904-455-50 1332a3947898…d4bfe170f9cd…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed Product Concepts# FDA-Initiated Inactive NDC Indexing# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 52904-455-02 Sinus Relief Severe Congestion 2 in 1 PACKET TABLET 2 2 52904-455-06 Sinus Relief Severe Congestion 1 in 1 CARTON TABLET 1 2 52904-455-50 Sinus Relief Severe Congestion 25 in 1 BOX TABLET 25 2
DailyMed Socrata Ingredients# Ingredient, Type, UNII table Ingredient Type UNII DailyMed label SPL version Uploaded ACETAMINOPHEN ACTIVE INGREDIENT 362O9ITL9D SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 GUAIFENESIN ACTIVE INGREDIENT 495W7451VQ SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 PHENYLEPHRINE HYDROCHLORIDE ACTIVE INGREDIENT 04JA59TNSJ SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 ACETAMINOPHEN ACTIVE MOIETY 362O9ITL9D SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 GUAIFENESIN ACTIVE MOIETY 495W7451VQ SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 PHENYLEPHRINE ACTIVE MOIETY 1WS297W6MV SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 CELLULOSE, MICROCRYSTALLINE INACTIVE INGREDIENT OP1R32D61U SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 FD&C RED NO. 40 INACTIVE INGREDIENT WZB9127XOA SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 MALTODEXTRIN INACTIVE INGREDIENT 7CVR7L4A2D SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 POVIDONE K30 INACTIVE INGREDIENT U725QWY32X SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 SODIUM STARCH GLYCOLATE TYPE A POTATO INACTIVE INGREDIENT 5856J3G2A2 SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 STARCH, CORN INACTIVE INGREDIENT O8232NY3SJ SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1 STEARIC ACID INACTIVE INGREDIENT 4ELV7Z65AP SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 1
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 52904-455 SINUS RELIEF SEVERE CONGESTION (ACETAMINOPHEN,GUAIFENESIN, PHENYLEPHRINE HCL) TABLET [SELECT CORPORATION] 2 Legacy NDC, 3 package rows 20180210_9196d2e1-c3ef-4b46-b10b-bbab08229cbb.zip
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 52904-455-02 52904045502 2 in 1 PACKET Historical 52904-455-06 52904045506 1 in 1 CARTON Historical 52904-455-50 52904045550 25 CARTON in 1 BOX (52904-455-50) > 1 PACKET in 1 CARTON (52904-455-06) > 2 TABLET in 1 PACKET (52904-455-02) 25 carton 2012-10-15 0000-00-00 No No Current